A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2018 Planned initiation date changed from 11 Jul 2018 to 10 May 2019.